To evaluate the use of positron emission tomography using [ 18 F]-fluorodeoxyglucose (FDG-PET) to assess the response to neoadjuvant radiotherapy and chemotherapy in patients with locally advanced esophageal cancer.
Objective
To evaluate the use of positron emission tomography using [ 18 F]-fluorodeoxyglucose (FDG-PET) to assess the response to neoadjuvant radiotherapy and chemotherapy in patients with locally advanced esophageal cancer.
Summary Background Data
Imaging modalities, including endoscopy, endoscopic ultrasound, computed tomography, and magnetic resonance imaging, currently used to evaluate response to neoadjuvant treatment in esophageal cancer do not reliably differentiate between responders and nonresponders.
Methods
Twenty-seven patients with histopathologically proven squamous cell carcinoma of the esophagus, located at or above the tracheal bifurcation, underwent neoadjuvant therapy consisting of external-beam radiotherapy and 5-fluorouracil as a continuous infusion. FDG-PET was performed before and 3 weeks after the end of radiotherapy and chemotherapy (be-fore surgery). Quantitative measurements of tumor FDG uptake were correlated with histopathologic response and patient survival.
Results
After neoadjuvant therapy, 24 patients underwent surgery. Histopathologic evaluation revealed less than 10% viable tumor cells in 13 patients (responders) and more than 10% viable tumor cells in 11 patients (nonresponders). In responders, FDG uptake decreased by 72% Ϯ 11%; in nonresponders, it decreased by only 42% Ϯ 22%. At a threshold of 52% decrease of FDG uptake compared with baseline, sensitivity to detect response was 100%, with a corresponding specificity of 55%. The positive and negative predictive values were 72% and 100%. Nonresponders to PET scanning had a significantly worse survival after resection than responders.
Conclusion
FDG-PET is a valuable tool for the noninvasive assessment of histopathologic tumor response after neoadjuvant radiotherapy and chemotherapy.
Most patients with esophageal squamous cell carcinoma have locally advanced disease at first diagnosis. Surgery remains the therapy of choice, provided a macroscopically and microscopically complete resection can be accomplished (R0 resection). 1, 2 Preoperative chemotherapy and combined radiotherapy and chemotherapy have been introduced with the primary objective of increasing the rate of complete resections by downsizing the primary tumor, with improvement of local tumor control and prevention of distant metastases. 3, 4 Nonresponders to neoadjuvant treatment seem to have a worse prognosis and disease-free and overall survival rates after complete resection compared with patients with comparable tumor stages treated by surgery alone. 5 Morphologic imaging modalities (endoscopy, endoscopic ultrasonography [EUS], computed tomography [CT], magnetic resonance imaging) do not reliably differentiate between viable tumor and inflammatory reactions, edema, and scar tissue. 6 -10 The need for noninvasive methods to differentiate between responders and nonresponders after neoadjuvant therapy for esophageal carcinoma is widely acknowledged. 11 Positron emission tomography (PET) using [ 18 F]-deoxyglucose (FDG) has been used to visualize enhanced glucose utilization in tumor tissue. Based on this biochemical signal, FDG-PET has been shown to identify primary tumors, regional lymph nodes, and distant metastases with considerable diagnostic accuracy. 12, 13 Markedly increased FDG uptake in squamous cell esophageal cancer has been documented in several studies. 14 -17 In breast cancer, sequential FDG-PET imaging has been shown to provide a sensitive means of early detection of tumor response to therapy. 18, 19 However, no information is available describing the role of FDG-PET for the noninvasive assessment of response to neoadjuvant therapy in esophageal cancer.
The purpose of this study was to use FDG-PET imaging prospectively in patients with locally advanced esophageal squamous cell cancer to assess the response to preoperative neoadjuvant radiotherapy and chemotherapy. Endpoints were the comparison of reduction in tumor FDG uptake with postoperative histopathologic tumor response and survival.
METHODS
Between November 1995 and March 2000, 27 patients with histologically proven esophageal squamous cell carcinoma were included in this study. Exclusion criteria were diabetes, peripheral vascular and coronary artery disease, or other contraindications for esophagectomy. 20, 21 Patients receiving prior treatment (chemotherapy, radiotherapy, laser therapy, or stent implantation) were not included. To determine the tumor stage precisely, patients underwent endoscopy, EUS, bronchoscopy (including brush cytology and biopsy), and CT. Patients with locally advanced esophageal carcinomas without distant metastases (uT3/4, N0/ϩ, M0), located at or above the tracheal bifurcation, who were eligible for surgery were included, and a baseline FDG-PET was obtained.
After these diagnostic procedures, patients underwent simultaneous radiotherapy and chemotherapy for 3 weeks. Assessment of tumor response by CT, endoscopy, EUS, and follow-up PET scan was performed 3 weeks after completion of therapy. Patients without signs of tumor progression or other contraindications for esophagectomy were scheduled to undergo surgery. Figure 1 summarizes the time schedule of the study protocol. The study protocol was designed to allow comparison of FDG-PET data and histopathologic evaluation of tumor tissue at close time points. It was approved by the institutional review board at the Technische Universität München. Written informed consent was obtained from all patients.
Neoadjuvant Treatment
Neoadjuvant therapy consisted of simultaneous radiotherapy and chemotherapy. The external radiotherapy was delivered by a two-field technique using a 10-to 15-MV photon beam of 2 Gray per fraction (per day), 5 fractions per week, to a total dose of 30 Gray. Simultaneously, chemotherapy with 5-fluoruracil was administered as a continuous infusion for 21 days at a daily dose of 300 mg/m 2 . 22 This regimen was chosen because in our experience it minimizes side effects while still producing response rates comparable to more aggressive schedules. 1, 3, 23, 24 
Clinical Response Evaluation
The clinical response evaluation was performed 3 weeks after the end of therapy based on the criteria defined by the World Health Organization. 25 The assessment of clinical response included repeated endoscopy, EUS, and CT scan. Endoscopic and EUS response was assessed by one investigator, judging the response based on macroscopic aspects of the tumor mass. The findings of the endoscopic investi- gations were documented on video. CT scans were obtained using a conventional technique after oral and intravenous administration of contrast. Pharmaceutical hypotonia was achieved by giving 40 mg butylscopolamine before scanning. Response was assessed by one experienced radiologist, measuring maximal tumor length and maximum wall thickness before and after treatment. Results of endoscopy, EUS, CT scan, and the clinical workup were discussed by the investigators, and response was defined by consensus. The results of the PET study were not known to the clinical investigators at the time of clinical response evaluation. If patients were found to have inoperable disease after neoadjuvant treatment, further palliative treatment was given.
PET Imaging
Patients fasted overnight before PET scanning to minimize the blood insulin level and to ensure standardized glucose metabolism in all patients. Blood glucose levels were measured before each PET examination. FDG with high specific activity was synthesized by nucleophilic fluorination. 26 For each PET scan, patients received an intravenous injection of 250 to 370 MBq FDG. Imaging was performed on an ECAT 951/R or ECAT EXACT PET scanner. (Siemens CTI, Knoxville, TN). Emission images of the tumor region of 20 minutes' duration were acquired 40 minutes after tracer injection. A transmission scan for attenuation correction was acquired after the emission scan. The duration of the transmission scan was 10 to 15 minutes, and approximately 4 million counts were acquired per slice. Emission data corrected for random events, dead time, and attenuation were reconstructed with filtered back-projection (Hanning filter; cutoff frequency 0.4 cycles/pixel, slice thickness 3.4 mm). The image counts/pixel were calibrated to activity concentration (Bq/mL). The resulting spatial resolution was approximately 8 mm at full width at half maximum.
Data Analysis
Attenuation-corrected PET images were normalized for the injected dose of FDG and the patient's body weight, resulting in parametric images representing regional standardized uptake values (SUVs) 27 : SUV ϭ (tissue activity concentration) ϫ (body weight)/(administered activity). For the quantitative evaluation of regional FDG uptake, regions of interest (ROIs) were manually placed over all tumors. A circular ROI of 1.5 cm was placed in the slice with maximum FDG uptake. If no focal FDG uptake was visible in the follow-up examinations, the ROI was placed in the same location as the previously identified lesion using the landmarks of the transmission images (apex of the lungs, bifurcation of the trachea) as a reference. SUVs were calculated using the average activity values in the ROI.
Surgical Therapy
All patients who were considered to be suitable for surgery and did not demonstrate tumor progression after neoadjuvant therapy were referred to surgery. Surgical therapy consisted of transthoracic en bloc esophagectomy with twofield lymphadenectomy in tumors located at and above the tracheal bifurcation. 28, 29 Cervical tumors were treated with a partial esophageal resection (sleeve resection). 30 Gastrointestinal continuity was maintained by a gastric pull-up in patients with tumors located at and above the tracheal bifurcation and with a free jejunal graft in patients with cervical tumors.
Histopathologic Evaluation
Resection specimens were fixed with formaldehyde (4%) for 24 hours. The complete tumor was cut into slices containing the entire esophagus wall marked with ink at all resection margins. Lymph nodes were prepared from the remaining perimuscular tissue, and the oral and aboral resection margins were sampled. The tissue was paraffinembedded and serial sections of each block were cut (5 m) and stained with hematoxylin and eosin and van Gieson stain. All specimens were classified by two experienced pathologists unaware of the clinical and PET data in accordance with the criteria of the International Union Against Cancer, 31 including the R classification and grading. The response to treatment was classified as complete, subtotal, partial, minimal remission, and no change in accordance with the criteria described by Mandard et al, 32 with modifications. Briefly, the percentage of viable residual tumor cells was assessed as follows. Complete response showed histologic fibrosis with or without inflammation extending through the different layers of the esophageal wall, but with no viable residual tumor cells. Subtotal response was characterized by the presence of less than 10% viable residual tumor cells, partial response by 10% to 50%, and minimal remission by more than 50% of viable residual tumor cells. No change was defined by the absence of any regressive changes. For statistical analysis, the histopathologic response of patients undergoing resection was classified into two groups: group 1 (responder) consisted of patients with complete and subtotal responses, and group 2 (nonresponder) included patients with partial and minimal response and no change.
Statistical Analysis
PET signals were expressed as mean Ϯ standard deviation, and differences between groups were tested with variance analysis or t test. For intraindividual comparison of tumor FDG uptake parameters before and after neoadjuvant therapy, a paired t test was used. Survival rates were calculated according to Kaplan-Meier 33 and tested with a log-rank test. 34 Differences in proportion of patients were analyzed by a chi-square Test. All tests were two-sided. P Ͻ .05 was considered significant.
To evaluate the diagnostic accuracy of a reduction in FDG uptake for assessment of histopathologic response, a receiver operating characteristic curve was calculated. This curve shows, for all observed changes of tumor FDG uptake, the percentage of responding and nonresponding tumors with an equal or greater reduction of FDG uptake. Thus, the sensitivity and specificity of a reduction in FDG uptake for assessment of histopathologic response can be determined for various cutoff values. In the present study, sensitivity was defined as the proportion of responding tumors that showed a reduction in FDG uptake that was equal to or greater than the cutoff value. The corresponding specificity was defined by the proportion of nonresponding tumors that showed a smaller decrease in FDG uptake than the cutoff value. By this definition, the positive predictive value of FDG-PET is the percentage of tumors with a greater decrease in FDG uptake than the cutoff value that prove to be responding. The negative predictive value is the percentage of tumors with a smaller decrease in FDG uptake than the cutoff value that prove to be nonresponding. Finally, the accuracy of PET imaging was defined as the number of correctly identified responding and nonresponding tumors divided by the total number of examined tumors. For all estimated parameters, 95% confidence intervals were calculated.
RESULTS

Demographic Data
The median age of the 27 patients was 52.9 years Ϯ 6.1 (range 37.8 -61). There were 4 female and 23 male patients. The primary tumor category on pretherapeutic staging was uT2 in 2 patients, uT3 in 23 patients, and uT4 in 2 patients. Seven (29.2%) tumors were located in the cervical esophagus and 17 (70.8%) in the intrathoracic esophagus. Eight (29.6%) patients had histologically well-differentiated tumors (G2) and 19 (70.4%) had moderately differentiated tumors (G3).
Clinical Response Evaluation
One patient (3.7%) had a complete remission, 11 patients (40.7%) had a partial remission, 5 patients (18.5%) had a minor remission, and 10 patients (37.1%) showed no change. Twenty-four patients (88.9%) were referred for surgery. All patients with complete, partial, and minor response and seven patients with no change underwent surgery. Three patients (11.1%) with no change received further palliative treatment because of new alcohol abuse and functional inoperability (Fig. 2) . For further analysis, patients with complete and partial remissions (n ϭ 12) were classified as clinical responders. All other patients were considered nonresponders (n ϭ 15). No influence of tumor location on clinical response was observed (P ϭ .18)
Surgery
All 24 patients referred to surgery after preoperative treatment underwent resection. A complete resection (R0) was achieved in 20 patients (83.4%), whereas 4 patients (16.6%) had histopathologically residual tumor in the radial resection margin (tumor bed). In seven patients (29.6%) with cervical carcinoma, an interposition of a free jejunal graft was performed. Therefore, 17 patients (70.4%) underwent a transthoracic en bloc resection and two-field lymphadenectomy followed by a reconstruction with a gastric tube with a left cervical anastomosis. The postoperative complication rate was 37.5% (9/24). One patient died after surgery of a myocardial infarction.
Histopathologic Workup and Response Evaluation
The distribution of the pT, pN, and pM category and the stage grouping is shown in Table 1 . The histopathologic response evaluation revealed complete response in 3 of 24 patients (12.5%), subtotal response in 10 patients (41.7%), partial response in 6 patients (25%), and minimal response in 5 patients (20.8%). There were no patients who had no change. Thus, group 1 (complete and subtotal response) consisted of 13 patients, group 2 (partial and minimal response) of 11 patients. Sixteen patients (66.7%) had no lymph node metastasis (pN0), whereas eight patients (33.3%) had distant lymph node metastasis. Comparing the pretherapeutic clinical staging with the postoperative histology, the neoadjuvant therapy was associated with down- 
FDG Uptake Before and After Treatment
All 27 patients underwent imaging before and after treatment, providing a total of 54 PET scans. There was no significant difference in plasma glucose levels at the time of tracer injection before treatment (96 Ϯ 15 mg/100 mL) and after treatment (94 Ϯ 13 mg/100 mL). All primary tumors demonstrated intensive FDG uptake at baseline. The SUV averaged 8.3 Ϯ 2.5 before treatment and decreased significantly to 3.3 Ϯ 1.5 after treatment (P Ͻ .0001). Figure 3 shows typical examples for FDG-PET studies obtained from two patients before and after neoadjuvant therapy. Cervical tumors had a mean decrease in FDG uptake of 47.6% Ϯ 14.8, whereas intrathoracic tumors showed a decrease of 62.5% Ϯ 24.2 (P ϭ .024).
Correlation of FDG-PET and Clinical Response
The decrease in SUV between both PET studies in patients with varying degrees of clinical response (complete response, n ϭ 1; partial response, n ϭ 11; minimal response, n ϭ 4; on change, n ϭ 8) was significantly correlated (P ϭ .006) with a decrease in SUV in responders (complete and partial responses, n ϭ 12) of 68% Ϯ 9.7% versus 49.07% Ϯ 26.2% in nonresponders (minimal response and no change, n ϭ 12).
Correlation of FDG-PET and Histopathology
There was a significant correlation between the decrease in FDG uptake and the individual histopathologic response categories (P ϭ .01). Specifically, patients with complete response (n ϭ 3) and subtotal response (n ϭ 10) (responders) had a decrease in SUV of 72.2% Ϯ 11.3%, whereas those with partial response (n ϭ 6) or minimal response (n ϭ 5) (nonresponders) showed a decrease of only 42.4% Ϯ 22% (P ϭ .002). There was little difference between patients with complete response (Ϫ77%) and subtotal response (Ϫ71%), as well as between those with partial and minimal response (Ϫ43%, Ϫ42%). The individual data are shown in Table 1 and Figure 4 . Measurements of the base-line PET showed FDG uptake of 8.9 Ϯ 2.6 with a decrease to follow-up PET of 2.3 Ϯ 0.7 in responders, and 7.8 Ϯ 2.3 with a decrease to 4.2 Ϯ 1.5 in nonresponders. Receiver operating characteristic curve analysis for assessment of histopathologic response by PET revealed an area under the curve of 9,161 (P ϭ .001 for comparison with an area under the curve of 5,000) for all patients who underwent resection (Fig. 5) . The area under the curve for patients who underwent transthoracic resection was 9,714 (P ϭ .001). Demanding a sensitivity of 100% (no his- Figure 3 . Examples of FDG-PET studies of responding and nonresponding tumors. In the baseline study, both tumors show intense FDG uptake. In the responding patient, FDG uptake decreased to background activity after neoadjuvant therapy (complete response). In contrast, FDG uptake by the nonresponding tumor shows little change after therapy (partial response). topathologic responder is incorrectly classified as a Table  2 ). The 95% confidence interval for specificity was 23% to 83%; for sensitivity it was 75% to 100%. Calculating the highest sensitivity and specificity (i.e., the data point of the receiver operating characteristic curve with the minimum distance from the 0% false-positive rate and the 100% true-positive rate) revealed a sensitivity of 85% and a specificity of 82%.
Survival
The median follow-up time was 3.7 years Ϯ 1.2 (range 0.8 -5) (11 of 27 patients were alive as of this writing). The overall 1-, 2-, and 3-year survival rates were 63.8% Ϯ 9.7%, 29.9% Ϯ 10.6%, and 19.9% Ϯ 10.8%, with a median survival of 18.7 months Ϯ 2 (confidence interval 14.8 -22.6) (see Fig. 5 ). Tumor location had no significant influence on survival (P ϭ .051). Patients with a decrease in the FDG uptake of less than 52% had a significantly (P Ͻ .0001) shorter median survival time (8.8 months Ϯ 2.7) compared with patients with an SUV decrease of 52% ormore (22.5 months Ϯ 2.5). Analyzing only patients who underwent resection (n ϭ 24) revealed a median survival of 22.5 months Ϯ 2.4 in patients with a decrease in FDG uptake of 52% or more and 6.7 months Ϯ 5 in those with a decrease in FDG uptake of less than 52% (P Ͻ .0001) (Fig. 6). Investigating only patients who underwent transthoracic resection revealed a median survival of 34 months Ϯ 12 in patients with a decrease in the FDG signal of 52% or more and 12 months Ϯ 8 in patients with a decrease of less than 52% (P ϭ .003) ( Fig. 7) .
DISCUSSION
In esophageal cancer, clinical response evaluation after neoadjuvant treatment is limited by the lack of noninvasive techniques that allow differentiation between responders and nonresponders. 6 -10 The results of the present study show that metabolic signals measured by FDG-PET are sensitive and specific for identifying responders to neoadjuvant therapy.
The decrease in metabolic activity in tumor tissue was more closely related to histopathologic outcome than data derived from the clinical evaluation of patients using other imaging approaches. This difference is best explained by the limitations of morphologic criteria to define the extent of malignant cells. In addition, neoadjuvant therapy may lead to inflammatory reactions associated with edema, which may mask the loss of tumor tissue. However, the number of patients studied in this population was too small to provide a statistically valid comparison of the imaging modalities for the assessment of response to neoadjuvant therapy.
It has been hypothesized that biochemical changes in tumor tissue induced by therapy precede the change in tumor size. 19, 35, 36 Therefore, imaging of tumor metabolism is expected to provide a sensitive means of detecting response to therapy. A recent study showed that FDG uptake in lymphomas decreases as early as 7 days after the start of therapy. 35 Our data clearly show that the decrease in tumor-FDG uptake correlates well with the results of histopathologic response evaluation. This confirms experimental data showing a close correlation between FDG uptake and the extent of viable tumor cells. 37 Previous studies from our laboratory evaluating the reproducibility of the FDG signal showed that the tumor glucose utilization rate is stable without therapeutic interventions for the time period of the chosen study protocol. The interstudy variability of repeated FDG measurements was less than 20%. 38 The reported decrease in SUV values in our study population is clearly beyond the range of interstudy variability of FDG uptake and is therefore specific for a therapy-induced effect.
The histopathologic evaluation of the whole tumor bed with adjoining areas served as the gold standard for assessing response to neoadjuvant therapy. This approach minimizes potential errors in histopathologic response evaluation resulting from posttherapeutic tumor heterogeneity. A previously published scoring system that has been shown to be of prognostic relevance was used for classifying posttherapeutic tumor regression in the resected specimen. 32 This scoring system is based on the ratio of fibrosis versus viable tumor. However, the differentiation of therapy-induced fibrosis from preexisting tumor desmoplasia may be difficult in individual cases. Histopathologic assessment may overestimate tumor regression after neoadjuvant treatment, especially in patients with minimal response. However, in patients with complete response, it cannot be excluded that single viable tumor cells have been overlooked, although the complete tumor bed has been examined histopathologically. Therefore, we grouped patients with complete and subtotal responses as responders and those in the remaining categories as nonresponders.
On the basis of these results and our previous experience in squamous cell carcinoma of the esophagus, we suggest the following protocol for the use of PET in the management of patients after neoadjuvant treatment. Responders identified by PET should undergo a consecutive resection. Nonresponders should not be referred to surgery. This is substantiated by two observations. First, microscopic residual tumor tissue cannot be detected by PET, suggesting that an R0 resection is still required in responders. Second, nonresponders have such a poor prognosis (median survival 9 months) that it appears questionable whether they would benefit from surgical resection. However, this concept needs to be confirmed prospectively in larger patient groups to define the role of PET imaging compared with conventional response evaluation.
In conclusion, FDG-PET is a promising noninvasive technique for identifying response to neoadjuvant therapy in patients with squamous cell carcinoma of the esophagus and may significantly affect patient management.
